Vepdegestrant Earns FDA Nod for ESR1-Mutated Breast Cancer

by | May 1, 2026 | Health

Spread the love
Approval was based on findings from the phase 3 VERITAC-2 trial showing significantly improved PFS for patients with ESR1-mutated disease.
Medscape Medical News

Written By

Written by Albert Pham, News Curator and Blogger

Related Posts

0 Comments